Alcon (ALC) announced the full U.S. commercial launch of Voyager DSLT, the first Direct Selective Laser Trabeculoplasty device for treating glaucoma and ocular hypertension. The automated device delivers 120 laser pulses without requiring a gonio lens, streamlining the treatment process for nearly 5 million Americans diagnosed with glaucoma.Key features include an intuitive touchscreen interface and SureTrac eye-tracking technology for precise delivery. Clinical data shows that 62% of DSLT participants were medication-free at 12 months, and 92.5% would recommend the treatment to others. The device will be showcased at the 2025 American Glaucoma Society meeting in Washington, D.C.This launch expands Alcon's glaucoma portfolio, which includes Hydrus Microstent, EX-PRESS Glaucoma Filtration Device, and pharmaceutical drops.